Jacqueline Clavel

Jacqueline Clavel

Auto-generated profile, based on publicly available information

Jacqueline Clavel

INSERM, Villejuif, France

Research Focus & Metrics

Academic Career Length

43Years (1984-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2014 in The Lancet Oncology
Verified
Journal Article
Closed access
Gemma GattaGemma Gatta
Gemma Gatta
LBLaura Botta
Laura Botta
SRSilvia Rossi
Silvia Rossi
TATiiu Aareleid
Tiiu Aareleid
MBMagdalena Bielska-Lasota
Magdalena Bielska-Lasota
RPRafael Peris-Bonet
Rafael Peris-Bonet

8 March 2006 in International Archives of Occupational and Environmental Health
Verified
Journal Article
Closed access
PDF file
AFA. Fouillet
A. Fouillet
GRG. Rey
G. Rey
FLF. Laurent
F. Laurent
GPG. Pavillon
G. Pavillon
SBS. Bellec
S. Bellec
DHDenis Hémon
Denis Hémon

1 August 2014 in Journal of the National Cancer Institute Monographs
Verified
Journal Article
Open access
PDF file
LMLindsay M. Morton
Lindsay M. Morton
SSSusan L. Slager
Susan L. Slager
JCJames R. Cerhan
James R. Cerhan
SWSophia S. Wang
Sophia S. Wang
CVClaire Vajdic
Claire Vajdic
JSJoshua N. Sampson
Joshua N. Sampson
Non-Hodgkin lymphoma (NHL) comprises biologically and clinically heterogeneous subtypes. Previously, study size has limited the ability to compare and contrast the risk factor profiles among these heterogeneous subtypes. We pooled individual-level data from 17 471 NHL cases and 23 096 controls in 20 case–control studies from the International Lymphoma Epidemiology Consortium (InterLymph). We estimated the associations, measured as odds ratios, between each of 11 NHL subtypes and self-reported medical history, family history of hematologic malignancy, lifestyle factors, and occupation. We then assessed the heterogeneity of associations by evaluating the variability (Q value) of the estimated odds ratios for a given exposure among subtypes. Finally, we organized the subtypes into a hierarchical tree to identify groups that had similar risk factor profiles. Statistical significance of tree partitions was estimated by permutation-based P values (PNODE). Risks differed statistically significantly among NHL subtypes for medical history factors (autoimmune diseases, hepatitis C virus seropositivity, eczema, and blood transfusion), family history of leukemia and multiple myeloma, alcohol consumption, cigarette smoking, and certain occupations, whereas generally homogeneous risks among subtypes were observed for family history of NHL, recreational sun exposure, hay fever, allergy, and socioeconomic status. Overall, the greatest difference in risk factors occurred between T-cell and B-cell lymphomas (PNODE < 1.0×10−4), with increased risks generally restricted to T-cell lymphomas for eczema, T-cell-activating autoimmune diseases, family history of multiple myeloma, and occupation as a painter. We further observed substantial heterogeneity among B-cell lymphomas (PNODE < 1.0×10−4). Increased risks for B-cell-activating autoimmune disease and hepatitis C virus seropositivity and decreased risks for alcohol consumption and occupation as a teacher generally were restricted to marginal zone lymphoma, Burkitt/Burkitt-like lymphoma/leukemia, diffuse large B-cell lymphoma, and/or lymphoplasmacytic lymphoma/Waldenström macroglobulinemia. Using a novel approach to investigate etiologic heterogeneity among NHL subtypes, we identified risk factors that were common among subtypes as well as risk factors that appeared to be distinct among individual or a few subtypes, suggesting both subtype-specific and shared underlying mechanisms. Further research is needed to test putative mechanisms, investigate other risk factors (eg, other infections, environmental exposures, and diet), and evaluate potential joint effects with genetic susceptibility.

7 February 2008 in Pediatric Blood & Cancer
Verified
Journal Article
Closed access
PDF file
AGAurélie Guyot‐Goubin
Aurélie Guyot‐Goubin
JDJean Donadieu
Jean Donadieu
MBMohamed Barkaoui
Mohamed Barkaoui
SBStéphanie Bellec
Stéphanie Bellec
CTCaroline Thomas
Caroline Thomas
JCJacqueline Clavel
Jacqueline Clavel

13 April 2009 in Annals of Neurology
Verified
Journal Article
Closed access
PDF file
AEAlexis Elbaz
Alexis Elbaz
JCJacqueline Clavel
Jacqueline Clavel
PRPaul J. Rathouz
Paul J. Rathouz
FMFrédéric Moisan
Frédéric Moisan
JGJean‐Philippe Galanaud
Jean‐Philippe Galanaud
CTChristophe Tzourio
Christophe Tzourio

1 May 2010 in European Journal Of Cancer Prevention
Verified
Journal Article
Closed access
BLBrigitte Lacour
Brigitte Lacour
AGAurélie Guyot-Goubin
Aurélie Guyot-Goubin
SGSandra Guissou
Sandra Guissou
SBStéphanie Bellec
Stéphanie Bellec
EDEMMANUEL DESANDES
EMMANUEL DESANDES
JCJacqueline Clavel
Jacqueline Clavel
The French National Registry of Childhood Haematopoietic Malignancies and the French National Registry of Childhood Solid Tumours jointly ensure the surveillance of cancer in children aged less than 15 years in mainland France. During the period 2000–2004, the registries recorded a total of 8473 cases: 3446 cases of haematological malignancies and 5027 cases of solid tumours. The average number of sources per case was 2.7 and diagnosis was documented by cytology/histology in 94% of cases, ensuring high quality data. The age-standardized incidence rate for all cancers combined was 156.6 cases per million children per year, with a sex ratio of 1.2. The most frequent cancers were leukaemia (29%), central nervous system tumour (23%), lymphoma (12%) and neuroblastoma (8%). In France, an estimated one out of every 440 children presents with cancer before the age of 15 years. The incidence rates are close to those of other industrialized countries, but somewhat higher than those estimated by the French local registries for the period 1990–1999, probably because of improved methodology or perhaps a real increase in some rates. The French National Registries of Childhood Cancer have shown that they are able to fulfil public health surveillance missions satisfactorily and support the national programme for research on childhood cancer.